Reason for request
Re-assessment of the actual benefit at the request of the Transparency
Clinical Benefit
| Low |
Le service médical rendu par MEGACE 160 mg est faible dans le traitement palliatif des carcinomes du sein.
|
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
GVgFVjCqx2jkzwvz
Listen
